Key Metrics
CiteScore 

5.3
Eigenfactor 

0.001 - 0.005
H-Index 

29
Impact Factor 

< 5
SJR 

Q2Neurology

SNIP 

1.21
Recommended pre-submission checks
Powered by 

Topics Covered on Neurology and Therapy
Neurology and Therapy Journal Specifications
Indexed in the following public directories
Web of Science
Scopus
DOAJ
SJR
| Overview | |
| Publisher | SPRINGER LONDON LTD |
| Language | English |
| Frequency | Semi-annual |
| Article Processing Charges | EUR 5500 | USD 6850 | GBP 4700 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Semi-annual |
| Publication Start Year | 2012 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 6 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Neurology and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Neurology and Therapy
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
- 1 Jun 2026
- Neurology and therapy
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
- 7 May 2026
- Neurology and therapy
Real-World Effectiveness and Safety of Ofatumumab: Analysis of BCell Depletion, Comorbidities and Ethnicity in a Spanish Cohort.
- 6 May 2026
- Neurology and therapy
Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.
- 6 May 2026
- Neurology and therapy
Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.
- 6 May 2026
- Neurology and therapy
Treatment Preferences for Subcutaneous ImmunoglobulinAmong Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment.
- 6 May 2026
- Neurology and therapy
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
- 1 Jun 2026
- Neurology and therapy
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
- 7 May 2026
- Neurology and therapy
Real-World Effectiveness and Safety of Ofatumumab: Analysis of BCell Depletion, Comorbidities and Ethnicity in a Spanish Cohort.
- 6 May 2026
- Neurology and therapy
Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.
- 6 May 2026
- Neurology and therapy
Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.
- 6 May 2026
- Neurology and therapy
Treatment Preferences for Subcutaneous ImmunoglobulinAmong Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment.
- 6 May 2026
- Neurology and therapy